N-Methyl-3,3-methylenoxypiperidin | 58346-62-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: N-Methyl-3,3-methylenoxypiperidin
• 英文别名: 5-methyl-1-oxa-5-aza-spiro[2.5]octane；5-Methyl-1-oxa-5-azaspiro[2.5]octane；7-methyl-1-oxa-7-azaspiro[2.5]octane
• CAS: 58346-62-6
• 化学式: C₇H₁₃NO
• 分子量: 127.186
• InChiKey: YACYIHCZKDULJS-UHFFFAOYSA-N

物化性质

• 沸点：
  60-63 °C(Press: 14 Torr)
• 密度：
  1.05±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  15.8
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-Methyl-3,3-methylenoxypiperidin 生成 (3-Chloro-1-methyl-piperidin-3-yl)-methanol
  参考文献：
  名称：

  IKEGAMI S.; OHISHI J.; AKABOSHI S., CHEM. AND PHARM. BULL. , 1975, 23, NO 11, 2701-2710

  摘要：

  DOI：

文献信息

• Modulators of 11- beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
  申请人：Zhuo Jincong

  公开号：US20070208001A1

  公开（公告）日：2007-09-06

  The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1 and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1.

  本发明涉及11-β羟基类固醇脱氢酶1型的抑制剂及其药物组合物。本发明的化合物可用于治疗与11-β羟基类固醇脱氢酶1型的表达或活性相关的各种疾病。
• HETEROCYCLIC PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
  申请人：Ko S. Soo

  公开号：US20070299057A9

  公开（公告）日：2007-12-27

  The present application describes modulators of CCR3 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases.

  本申请描述了CCR3调节剂的化学式(I)或其药学上可接受的盐形式，可用于预防哮喘和其他过敏性疾病。
• INHIBITORS OF BRUTONS TYROSINE KINASE
  申请人：Pharmacyclics LLC

  公开号：US20210070748A1

  公开（公告）日：2021-03-11

  Disclosed herein are reversible and irreversible inhibitors of Bruton's tyrosine kinase (Btk). Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are described, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
• US7312222B2
  申请人：——

  公开号：US7312222B2

  公开（公告）日：2007-12-25